RCS - Roadside Real Estate - Update on Cambridge Sleep Sciences

Roadside Real EstateAnnouncement

18/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250218:nRSR4250Xa&default-theme=true

RNS Number : 4250X  Roadside Real Estate PLC  18 February 2025

Roadside Real Estate plc

 

("Roadside" or the "Company")

 

Update on Cambridge Sleep Sciences

Clinical trial results

Appointment of new chief executive officer

 

 

Roadside (AIM: ROAD) provides the following update on its 47.8% investment
holding in Cambridge Sleep Sciences ("CSS").

 

New clinical trial results released

CSS is pleased to announce the results of a second clinical trial of its
SleepEngine(TM) technology, demonstrating its effectiveness in helping to
improve the quality of adult sleep. The trial, led by Dr. Nigel Guest, showed
that all participants using SleepEngine(TM) technology reported an improvement
in their sleep quality.

 

The trial consisted of 19 adult participants with self-reported insomnia
lasting over six months, who used a SleepHub® device featuring the
SleepEngine(TM) technology for a period of 12 weeks. Their sleep quality was
measured using a sleep diary and the globally respected Pittsburgh Sleep
Quality Index, ("PQSI") rating scale ranging from 0 - 21, where higher scores
indicate poorer sleep quality and a change of three points is considered
significant.

 

From a baseline score of 11.21, the PSQI decreased by a statistically and
clinically significant level of 4.21 (p<0.001) to a score of 7, indicating
a substantial impact on sleep quality, taking trial participants from the
moderate to the mild sleep difficulty range. During the eight-week washout
phase, where the technology was no longer being used, its impact was still
experienced with the PSQI score decreasing further by 1.28 (p<0.012) to
5.72.

 

The latest trial results support the first unpublished trial of
SleepEngine(TM) from 2016, where 92% of participants experienced an
improvement in their sleep quality and an average increase in time asleep of
155 minutes. The latest trial results also reflect the anecdotal feedback
received from users of the SleepHub® device over the last four years.

 

Appointment of new chief executive officer of CSS

CSS has appointed Adam Rostom as its chief executive officer with a mandate to
accelerate CSS's commercial growth, seizing global licensing opportunities and
expanding its presence in the bedding and wellness markets. His leadership
will also drive the development of next-generation sleep solutions, working
with health tracking brands to integrate continuous biomarker tracking with
real-time sleep interventions.

 

Mr. Rostom has helped scale the businesses of household names including
Innocent Drinks, Dyson, OVO Energy, Babylon Health and Many Pets. As a PhD
biochemist with a passion for business, he has helped build and transform a
number of high-growth businesses, blending creativity with commercial impact.

 

Former chief executive officer of CSS, Julian Stone, has been appointed
President of the company, focusing on developing existing and new business
globally.

 

CSS expects to issue a trading update on or around 28 February, 2025.

 

Charles Dickson, Executive Chairman of Roadside, said:

"This statistically significant trial proves our belief in CSS's technology as
it continues to successfully help users improve their quality to sleep. We're
excited by the diverse range of licensing opportunities the business is
developing to find innovative new applications for its technology. I believe
Adam and Julian will form a formidable combination to deliver the next chapter
of CSS's story."

 

- Ends -

 

For more information

 

 Roadside Real Estate plc

 Charles Dickson, Executive Chairman

 c/o Montfort

 Cavendish Capital Markets Limited (Nomad and Joint Corporate Broker)

 Carl Holmes / Seamus Fricker (Corporate Finance)                               +44 (0)20 7220 0500

 Tim Redfern / Jamie Anderson (ECM)

 Stifel Nicolaus Europe Limited (Financial Adviser and Joint Corporate Broker)  +44 (0)20 7710 7600

 Mark Young

 Jonathan Wilkes-Green

 Catriona Neville

 Montfort

 Olly Scott                                                                     +44 (0)78 1234 5205

 Bella Leathley                                                                 +44 (0)74 7168 7266

 

 

About Roadside

Roadside is a real estate business focused on building and scaling a
high-quality portfolio of modern roadside retail assets, including modern EV
charging infrastructure.

 

About Cambridge Sleep Sciences Ltd

Cambridge Sleep Sciences Ltd, is a legacy Life Sciences investment in which
Roadside Real Estate plc holds a 47.8% interest. CSS develops technology which
improves natural sleep. Using the principles of neuroscience and cutting-edge
technology to enhance brain activity during sleep, its innovative solutions
aim to improve health, wellbeing and enhance quality of life.

 

Its SleepEngine(TM) technology has been developed and refined over fifteen
years by a team of researchers, scientists, sound engineers and medical
experts. This unique technology produces sounds which emulate the waves
created by the brain during sleep cycles. The sleep sounds guide the user's
brain through the sequence of healthy sleep cycles, helping them fall asleep
and achieve the quality of sleep they need in a consistent and optimal way.

 

Find out more at: www.cambridgesleepsciences.com
(http://www.cambridgesleepsciences.com/)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAVDLFFELLXBBX